Febbo PG - Search Results

1

Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.

Tay MH, Kaufman DS, Regan MM, Leibowitz SB, George DJ, Febbo PG, Manola J, Smith MR, Kaplan ID, Kantoff PW, Oh WK. Tay MH, et al. Among authors: febbo pg. Ann Oncol. 2004 Jun;15(6):974-8. doi: 10.1093/annonc/mdh221. Ann Oncol. 2004. PMID: 15151957 Free article.

2

Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.

Oh WK, Kaplan ID, Febbo P, Prisby J, Manola J, Kaufman DS, Kantoff PW. Oh WK, et al. Am J Clin Oncol. 2003 Jun;26(3):312-6. doi: 10.1097/01.COC.0000020921.08768.1F. Am J Clin Oncol. 2003. PMID: 12796607 Clinical Trial.

3

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.

Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. Taplin ME, et al. Among authors: febbo pg. Urology. 2005 Aug;66(2):386-91. doi: 10.1016/j.urology.2005.03.040. Urology. 2005. PMID: 16098367

4

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.

Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK. Ross RW, et al. Cancer. 2012 Oct 1;118(19):4777-84. doi: 10.1002/cncr.27416. Epub 2012 Jan 26. Cancer. 2012. PMID: 22282219 Free PMC article. Clinical Trial.

5

Systemic strategies for prostate cancer.

Armstrong AJ, Febbo PG, George DJ, Moul J. Armstrong AJ, et al. Among authors: febbo pg. Minerva Urol Nefrol. 2007 Mar;59(1):11-25. Minerva Urol Nefrol. 2007. PMID: 17431367 Review.

6

Debrisoquine hydroxylase (CYP2D6) and prostate cancer.

Febbo PG, Kantoff PW, Giovannucci E, Brown M, Chang G, Hennekens CH, Stampfer M. Febbo PG, et al. Cancer Epidemiol Biomarkers Prev. 1998 Dec;7(12):1075-8. Cancer Epidemiol Biomarkers Prev. 1998. PMID: 9865424

7

Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.

Anscher MS, Clough R, Robertson CN, Prosnitz LR, Dahm P, Walther P, Donatucci CF, Albala DM, Febbo P, George DJ, Sun L, Moul JW. Anscher MS, et al. Prostate Cancer Prostatic Dis. 2006;9(3):254-60. doi: 10.1038/sj.pcan.4500903. Epub 2006 Aug 1. Prostate Cancer Prostatic Dis. 2006. PMID: 16880828

8

A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis.

Kantoff PW, Febbo PG, Giovannucci E, Krithivas K, Dahl DM, Chang G, Hennekens CH, Brown M, Stampfer MJ. Kantoff PW, et al. Among authors: febbo pg. Cancer Epidemiol Biomarkers Prev. 1997 Mar;6(3):189-92. Cancer Epidemiol Biomarkers Prev. 1997. PMID: 9138662

9

The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer.

Febbo PG, Kantoff PW, Platz EA, Casey D, Batter S, Giovannucci E, Hennekens CH, Stampfer MJ. Febbo PG, et al. Cancer Res. 1999 Dec 1;59(23):5878-81. Cancer Res. 1999. PMID: 10606227 Clinical Trial.

10

No association between the I105V polymorphism of the glutathione S-transferase P1 gene (GSTP1) and prostate cancer risk: a prospective study.

Shepard TF, Platz EA, Kantoff PW, Nelson WG, Isaacs WB, Freije D, Febbo PG, Stampfer MJ, Giovannucci E. Shepard TF, et al. Among authors: febbo pg. Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1267-8. Cancer Epidemiol Biomarkers Prev. 2000. PMID: 11097238 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

95 results

Search Page